Our studies continue on the molecular pathology of JC virus and human glial cells in culture, and more recently, with human brain tissue sections from infected patients wth progressive multifocal leukoencephalopathy (PML). Experiments have focues at the intracellular level describing the nature of viral persistance in the CNS, pathogenesis of PML as a demyelinating disease, and the mechanisms of generic regulation of the viral and cellular genes involved. Our results include solving the biggest problems that working with JC has presented, namely the host and tissue restriction for growth to primary human fetal glial cells in culture. We have estalbished an immortalized line of human fetal astroglial cells using a mutant transforming gene of SV40. These cells are able to produce infectious JCV and have allowed us to examine the kinetics of CV DNA replication and T protein synthesis. We have also found that the SV40 T protein made in human glial cells complexes with a glial cell protein, p53, and stablizes this protein in the cell. The JCV T protein does not appear to complex with the p53 protein, perhaps due to confirmational differences between the T proteins of SV40 and JCV. Additional evidence for such differences came from our experiments suggesting alkylation of cycteine residues of the JCV T protein was necessary in order to resolve the immunoprecipitated T protein using denaturing gel electrophoresis. This was not necessary for either the T proteins of SV40 or the related human BK virus. Studies of paraffin embedded or fozen brain tissue from PML patients showed the presence of JCV DNA using in situ hyridization and correlated with the detection of viral capsid antigen using immunocytochemical tests. These studies also revealed that aligodendroglian cells are the main target for JCV gene expression but that bizarre astrocyctes present in PML plaques showed JCV DNA and capsid antigen. This latter finding questions role the of JC virus may have in the pathogenesis of malignant gliomas in the general population that has been suggested by others.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Intramural Research (Z01)
Project #
1Z01NS001983-14
Application #
4696800
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
1985
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Major, Eugene O (2009) Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies. Annu Rev Med :
Linda, Hans; von Heijne, Anders; Major, Eugene O et al. (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081-7
Major, Eugene O (2009) Reemergence of PML in natalizumab-treated patients--new cases, same concerns. N Engl J Med 361:1041-3
Bohl, Daniel L; Brennan, Daniel C; Ryschkewitsch, Caroline et al. (2008) BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 43:184-9
Houff, Sidney A; Berger, Joseph; Major, Eugene O (2008) Response to Linberg et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 199:160-161
Roseti, Livia; Facchini, Andrea; De Franceschi, Luciana et al. (2007) Induction of original phenotype of human immortalized chondrocytes: a quantitative gene expression analysis. Int J Mol Med 19:89-96
Ravichandran, Veerasamy; Jensen, Peter N; Major, Eugene O (2007) MEK1/2 inhibitors block basal and transforming growth factor 1beta1-stimulated JC virus multiplication. J Virol 81:6412-8
Ravichandran, Veerasamy; Major, Eugene O (2006) Viral proteomics: a promising approach for understanding JC virus tropism. Proteomics 6:5628-36
Li, Jongming; Melenhorst, Jos; Hensel, Nancy et al. (2006) T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J Gen Virol 87:2951-60
Yousry, Tarek A; Major, Eugene O; Ryschkewitsch, Caroline et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924-33

Showing the most recent 10 out of 41 publications